Patents by Inventor Bonnee Rubinfeld

Bonnee Rubinfeld has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • WNT ANTAGONISTS AND THEIR USE IN THE DIAGNOSIS AND TREATMENT OF WNT-MEDIATED DISORDERS
    Publication number: 20080299136
    Abstract: The present invention provides for chimeric Wnt antagonists comprising a Frz domain component derived from a Frizzled protein, a secreted Frizzled related protein or Ror protein and an Fc immunoglobulin component, and their use in the treatment and diagnostic detection of cellular Wnt signaling and Wnt-mediated disorders, including cancer.
    Type: Application
    Filed: September 7, 2007
    Publication date: December 4, 2008
    Applicant: Genentech, Inc.
    Inventors: James A. Ernst, Paul Polakis, Bonnee Rubinfeld, Venita I. DeAlmeida
  • Compositions and methods for diagnosing/treating disease based on beta-catenin/transcription factor interactions
    Publication number: 20020115109
    Abstract: Methods and compositions are described that are useful for diagnosing and/or treating disease arising from unwanted cell growth, preferably cancer, involving diagnosing cells for stabilized beta-catenin, or treating cells with compounds that disrupt or alter the formation of a complex consisting of beta-catenin/transcription factor, where the transcription factor is a member of the Lef/Tcf family.
    Type: Application
    Filed: November 2, 2001
    Publication date: August 22, 2002
    Inventors: Paul Polakis, Bonnee Rubinfeld
  • Modulators of BRCA1 activity
    Patent number: 5948643
    Abstract: Compositions of matter consisting of a family of related nucleotide sequences that encode proteins, termed BRCA1 Modulator Proteins, that bind to the tumor suppressor gene product BRCA1, and methods of using the nucleotide sequences and the proteins encoded thereby, to diagnose and/or treat disease where the BRCA1 Modulator Proteins have an apparent molecular weight of 45-97 kdaltons and are characterized by having at least one leucine zipper domain, and optionally a zinc finger domain.
    Type: Grant
    Filed: August 13, 1997
    Date of Patent: September 7, 1999
    Assignee: Onyx Pharmaceuticals, Inc.
    Inventors: Bonnee Rubinfeld, Paul G. Polakis, Carol Lingenfelter, Terilyn T. Vuong
  • Native type II GAP, methods for purifying various GAPs and uses of GAPs to diagnose cancer
    Patent number: 5830684
    Abstract: Native Type II GAP (GTPase activating protein), its uses in cancer diagnosis, and methods for obtaining and purifying native and recombinant Types I and II GAPs are described.
    Type: Grant
    Filed: December 7, 1990
    Date of Patent: November 3, 1998
    Assignee: Chiron Corporation
    Inventors: Robert Halenbeck, Kirston Koths, Francis P. McCormick, Bonnee Rubinfeld, Edward C. O'Rourke, Robin Clark, Gail L. Wong, George Martin
  • GTPase activating protein fragments
    Patent number: 5763573
    Abstract: Peptides, that inhibit GAP stimulated ras p21 hydrolysis of GTP; peptides that mediate dissociation of GDP from ras p21-GTP complex; and antibodies to the peptides are described. These peptides are useful as cancer diagnostics and therapeutics, particularly to detect cancer cells with an over expression of normal or oncogenic ras p21 protein and to treat cancer caused by ras oncogene. Methods for assaying products of oncogenes using the described peptides and antibodies are also disclosed. Method for treating cancer caused by ras oncogenes is also disclosed.
    Type: Grant
    Filed: January 30, 1995
    Date of Patent: June 9, 1998
    Assignee: Chiron Corporation
    Inventors: Francis P. McCormick, Gail L. Wong, Paul G. Polakis, Bonnee Rubinfeld
  • Gap gene sequences
    Patent number: 5760203
    Abstract: Guanosine triphosphatase activating protein (GAP) DNA sequences are described that are useful as cancer diagnostics, particularly to detect cancer cells that express the ras oncogene protein p21 by measuring the level of GAP gene expression or amplification.
    Type: Grant
    Filed: February 2, 1994
    Date of Patent: June 2, 1998
    Assignee: Chiron Corporation
    Inventors: Gail L. Wong, George Martin, Francis P. McCormick, Bonnee Rubinfeld, Edward C. O'Rourke, Robin Clark